Muscarinic receptors as model targets and antitargets for structure-based ligand discovery

Molecular Pharmacology

Volumn 84, Issue 4, 2013, Pages 528-540

  Kruse, Andrew C ^a   Weiss, Dahlia R ^b   Rossi, Mario ^d   Hu, Jianxin ^d   Hu, Kelly ^d   Eitel, Katrin ^e   Gmeiner, Peter ^e   Wess, Jürgen ^d   Kobilka, Brian K ^a   Shoichet, Brian K ^b,c  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF TORONTO   (Canada)

^d NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES   (United States)

^e UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

[ 1 [ 2 [( 4 ( 4 METHOXYPHENYL)OXAN 4 YL)FORMAMIDO]ETHYL] 2 METHYL 1H IMIDAZOL 3 IUM]; [ 3 ( 4,6 DIMETHYL 1,3 DIOXO 1,3,3A,4,7,7A HEXAHYDRO 2H ISOINDOL 2 YL) N,N,N TRIMETHYL 2 PROPANAMINIUM IODIDE]; AMINO ACID; ATROPINE; G PROTEIN COUPLED RECEPTOR; INSULIN; LIGAND; MUSCARINIC AGENT; MUSCARINIC M2 RECEPTOR; MUSCARINIC M3 RECEPTOR; MUSCARINIC RECEPTOR; MUSCARINIC RECEPTOR BLOCKING AGENT; OXO M; QUINUCLIDINYL BENZILATE; UNCLASSIFIED DRUG; CHOLINERGIC RECEPTOR STIMULATING AGENT; PROTEIN BINDING;

AMINO ACID SUBSTITUTION; ANIMAL CELL; ARTICLE; CELL LINE; CONTROLLED STUDY; DRUG CONFORMATION; DRUG RECEPTOR BINDING; DRUG SELECTIVITY; DRUG TARGETING; HYDROPHOBICITY; INSULIN RELEASE; LIGAND BINDING; MOLECULAR DOCKING; MOLECULE; NONHUMAN; PANCREAS ISLET BETA CELL; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN FUNCTION; PROTEIN STRUCTURE; ANIMAL; CHEMISTRY; CHO CELL LINE; CRICETULUS; DRUG DELIVERY SYSTEM; DRUG DEVELOPMENT; HAMSTER; HUMAN; INSECT; METABOLISM; MOUSE; PHYSIOLOGY; RAT; TRENDS;

ANIMALS; CELL LINE; CHO CELLS; CHOLINERGIC AGENTS; CRICETINAE; CRICETULUS; DRUG DELIVERY SYSTEMS; DRUG DISCOVERY; HUMANS; INSECTS; LIGANDS; MICE; PROTEIN BINDING; RATS; RECEPTORS, MUSCARINIC;

EID: 84884685355     PISSN: 0026895X     EISSN: 15210111     Source Type: Journal    
DOI: 10.1124/mol.113.087551     Document Type: Article

References (48)

1. Avlani VA, Langmead CJ, Guida E, Wood MD, Tehan BG, Herdon HJ, Watson JM, Sexton PM, and Christopoulos A (2010) Orthosteric and allosteric modes of interaction of novel selective agonists of the M1 muscarinic acetylcholine receptor. Mol Pharmacol 78:94-104.
2. Barlow RB and Tubby JH (1974) Actions of some esters of 3,3-dimethylbutan-1-ol (the carbon analogue of choline) on the guinea-pig ileum. Br J Pharmacol 51:95-100.
3. Ballesteros J and Weinstein H (1995) Integrated methods for modeling G-protein coupled receptors. Methods Neurosci 25:366-428.
4. Blüml K, Mutschler E, and Wess J (1994) Functional role in ligand binding and receptor activation of an asparagine residue present in the sixth transmembrane domain of all muscarinic acetylcholine receptors. J Biol Chem 269:18870-18876. (Pubitemid 24226200)
5. Caccamo A, Fisher A, and LaFerla FM (2009) M1 agonists as a potential disease-modifying therapy for Alzheimer's disease. Curr Alzheimer Res 6:112-117.
6. Carlsson J, Coleman RG, Setola V, Irwin JJ, Fan H, Schlessinger A, Sali A, Roth BL, and Shoichet BK (2011) Ligand discovery from a dopamine D3 receptor homology model and crystal structure. Nat Chem Biol 7:769-778.
7. Carlsson J, Yoo L, Gao ZG, Irwin JJ, Shoichet BK, and Jacobson KA (2010) Structure-based discovery of A2A adenosine receptor ligands. J Med Chem 53:3748-3755.
8. Chan WY, McKinzie DL, Bose S, Mitchell SN, Witkin JM, Thompson RC, Christopoulos A, Lazareno S, Birdsall NJM, and Bymaster FP et al. (2008) Allosteric modulation of the muscarinic M4 receptor as an approach to treating schizophrenia. Proc Natl Acad Sci USA 105:10978-10983.
9. Conn PJ, Christopoulos A, and Lindsley CW (2009a) Allosteric modulators of GPCRs: a novel approach for the treatment of CNS disorders. Nat Rev Drug Discov 8:41-54.
10. Conn PJ, Jones CK, and Lindsley CW (2009b) Subtype-selective allosteric modulators of muscarinic receptors for the treatment of CNS disorders. Trends Pharmacol Sci 30:148-155.
11. 1 receptor antagonists. Bioorg Med Chem 20:5254-5261.
12. de Graaf C, Kooistra AJ, Vischer HF, Katritch V, Kuijer M, Shiroishi M, Iwata S, Shimamura T, Stevens RC, and de Esch IJ et al. (2011) Crystal structure-based virtual screening for fragment-like ligands of the human histamine H(1) receptor. J Med Chem 54:8195-8206.
13. Durrant JD and McCammon JA (2010) Computer-aided drug-discovery techniques that account for receptor flexibility. Curr Opin Pharmacol 10:770-774.
14. Evers A and Klebe G (2004) Successful virtual screening for a submicromolar antagonist of the neurokinin-1 receptor based on a ligand-supported homology model. J Med Chem 47:5381-5392. (Pubitemid 39382788)
15. Gaulton A, Bellis LJ, Bento AP, Chambers J, Davies M, Hersey A, Light Y, McGlinchey S, Michalovich D, and Al-Lazikani B et al. (2012) ChEMBL: a large-scale bioactivity database for drug discovery. Nucleic Acids Res 40 (Database issue):D1100-D1107.
16. Gautam D, Ruiz de Azua I, Li JH, Guettier JM, Heard T, Cui Y, Lu H, Jou W, Gavrilova O, and Zawalich WS, et al. (2010) Beneficial metabolic effects caused by persistent activation of beta-cell M3 muscarinic acetylcholine receptors in transgenic mice. Endocrinology 151:5185-5194.
17. Gregory KJ, Hall NE, Tobin AB, Sexton PM, and Christopoulos A (2010) Identification of orthosteric and allosteric site mutations in M2 muscarinic acetylcholine receptors that contribute to ligand-selective signaling bias. J Biol Chem 285:7459-7474.
18. Haga K, Kruse AC, Asada H, Yurugi-Kobayashi T, Shiroishi M, Zhang C, Weis WI, Okada T, Kobilka BK, and Haga T, et al. (2012) Structure of the human M2 muscarinic acetylcholine receptor bound to an antagonist. Nature 482:547-551.
19. Heitz F, Holzwarth JA, Gies JP, Pruss RM, Trumpp-Kallmeyer S, Hibert MF, and Guenet C (1999) Site-directed mutagenesis of the putative human muscarinic M2 receptor binding site. Eur J Pharmacol 380:183-195. (Pubitemid 29469529)
20. Henzler AM and Rarey M (2011) Protein flexibility in structure-based virtual screening: from models to algorithms, in Virtual Screening (Sotriffer C ed) pp 223-244, Wiley-VCH Verlag GmbH & Co. KGaA, Weinheim, Germany.
21. Hert J, Willett P, Wilton DJ, Acklin P, Azzaoui K, Jacoby E, and Schuffenhauer A (2004) Comparison of topological descriptors for similarity-based virtual screening using multiple bioactive reference structures. Org Biomol Chem 2:3256-3266.
22. Irwin JJ and Shoichet BK (2005) ZINC - a free database of commercially available compounds for virtual screening. J Chem Inf Model 45:177-182. (Pubitemid 40736970)
23. Irwin JJ, Shoichet BK, Mysinger MM, Huang N, Colizzi F, Wassam P, and Cao Y (2009) Automated docking screens: a feasibility study. J Med Chem 52:5712-5720.
24. Irwin JJ, Sterling T, Mysinger MM, Bolstad ES, and Coleman RG (2012) ZINC: A Free Tool to Discover Chemistry for Biology. J Chem Inf Model 52:1757-1768.
25. Ishihara H, Asano T, Tsukuda K, Katagiri H, Inukai K, Anai M, Kikuchi M, Yazaki Y, Miyazaki JI, and Oka Y (1993) Pancreatic beta cell line MIN6 exhibits characteristics of glucose metabolism and glucose-stimulated insulin secretion similar to those of normal islets. Diabetologia 36:1139-1145. (Pubitemid 23314564)
26. Katritch V, Jaakola VP, Lane JR, Lin J, Ijzerman AP, Yeager M, Kufareva I, Stevens RC, and Abagyan R (2010) Structure-based discovery of novel chemotypes for adenosine A(2A) receptor antagonists. J Med Chem 53:1799-1809.
27. Kolb P, Rosenbaum DM, Irwin JJ, Fung JJ, Kobilka BK, and Shoichet BK (2009) Structure-based discovery of beta2-adrenergic receptor ligands. Proc Natl Acad Sci USA 106:6843-6848.
28. Kolb P, Phan K, Gao ZG, Marko AC, Sali A, and Jacobson KA (2012) Limits of ligand selectivity from docking to models: in silico screening for A(1) adenosine receptor antagonists. PLoS ONE 7:e49910.
29. Kruse AC, Hu J, Pan AC, Arlow DH, Rosenbaum DM, Rosemond E, Green HF, Liu T, Chae PS, and Dror RO et al. (2012) Structure and dynamics of the M3 muscarinic acetylcholine receptor. Nature 482:552-556.
30. Lorber DM and Shoichet BK (2005) Hierarchical docking of databases of multiple ligand conformations. Curr Top Med Chem 5:739-749. (Pubitemid 41179714)
31. Langmead CJ, Andrews SP, Congreve M, Errey JC, Hurrell E, Marshall FH, Mason JS, Richardson CM, Robertson N, and Zhukov A et al. (2012) Identification of novel adenosine A(2A) receptor antagonists by virtual screening. J Med Chem 55:1904-1909.
32. Li B, Scarselli M, Knudsen CD, Kim S-K, Jacobson KA, McMillin SM, and Wess J (2007) Rapid identification of functionally critical amino acids in a G protein-coupled receptor. Nat Methods 4:169-174. (Pubitemid 46454686)
33. Marlo JE, Niswender CM, Days EL, Bridges TM, Xiang Y, Rodriguez AL, Shirey JK, Brady AE, Nalywajko T, and Luo Q et al. (2009) Discovery and characterization of novel allosteric potentiators of M1 muscarinic receptors reveals multiple modes of activity. Mol Pharmacol 75:577-588.
34. May LT, Leach K, Sexton PM, and Christopoulos A (2007) Allosteric modulation of G protein-coupled receptors. Annu Rev Pharmacol Toxicol 47:1-51. (Pubitemid 46277033)
35. McMillin SM, Heusel M, Liu T, Costanzi S, and Wess J (2011) Structural basis of M3 muscarinic receptor dimer/oligomer formation. J Biol Chem 286:28584-28598.
36. Messer WS, Jr (2002) The utility of muscarinic agonists in the treatment of Alzheimer's disease. J Mol Neurosci 19:187-193.
37. Mohr K, Tränkle C, Kostenis E, Barocelli E, De Amici M, and Holzgrabe U (2010) Rational design of dualsteric GPCR ligands: quests and promise. Br J Pharmacol 159:997-1008.
38. Muchmore SW, Debe DA, Metz JT, Brown SP, Martin YC, and Hajduk PJ (2008) Application of belief theory to similarity data fusion for use in analog searching and lead hopping. J Chem Inf Model 48:941-948.
39. Mysinger MM and Shoichet BK (2010) Rapid context-dependent ligand desolvation in molecular docking. J Chem Inf Model 50: 1561-1573.
40. Mysinger MM, Weiss DR, Ziarek JJ, Gravel S, Doak AK, Karpiak J, Heveker N, Shoichet BK, and Volkman BF (2012) Structure-based ligand discovery for the protein-protein interface of chemokine receptor CXCR4. Proc Natl Acad Sci USA 109:5517-5522.
41. Negri A, Rives ML, Caspers MJ, Prisinzano TE, Javitch JA, and Filizola M (2013) Discovery of a Novel Selective Kappa-Opioid Receptor Agonist Using Crystal Structure-Based Virtual Screening. J Chem Inf Model 53:521-526.
42. Ruiz de Azua I, Scarselli M, Rosemond E, Gautam D, Jou W, Gavrilova O, Ebert PJ, Levitt P, and Wess J (2010) RGS4 is a negative regulator of insulin release from pancreatic β-cells in vitro and in vivo. Proc Natl Acad Sci USA 107:7999-8004.
43. Sabio M, Jones K, and Topiol S (2008) Use of the X-ray structure of the beta2-adrenergic receptor for drug discovery. Part 2: Identification of active compounds. Bioorg Med Chem Lett 18:5391-5395.
44. Totrov M and Abagyan R (2008) Flexible ligand docking to multiple receptor conformations: a practical alternative. Curr Opin Struct Biol 18:178-184.
45. Wei BQ, Weaver LH, Ferrari AM, Matthews BW, and Shoichet BK (2004) Testing a flexible-receptor docking algorithmin amodel binding site. J Mol Biol 337:1161-1182. (Pubitemid 38445058)
46. Weiss DR, Ahn S, Sassano MF, Kleist A, Zhu X, Strachan R, Roth BL, Lefkowitz RJ, and Shoichet BK (2013) Conformation guides molecular efficacy in docking screens of activated β-2 adrenergic G protein coupled receptor. ACS Chem Biol 8:1018-1026.
47. Wess J, Liu J, Blin N, Yun J, Lerche C, and Kostenis E (1997) Structural basis of receptor/G protein coupling selectivity studied with muscarinic receptors as model systems. Life Sci 60:1007-1014. (Pubitemid 27165569)
48. Wess J, Eglen RM, and Gautam D (2007) Muscarinic acetylcholine receptors: mutant mice provide new insights for drug development. Nat Rev Drug Discov 6:721-733. (Pubitemid 47342315)